Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer

  • Authors:
    • Riyad Bendardaf
    • Hanan Lamlum
    • Raija Ristamäki
    • Kari Syrjänen
    • Seppo Pyrhönen
  • View Affiliations

  • Published online on: November 1, 2008     https://doi.org/10.3892/or_00000101
  • Pages: 999-1004
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Colorectal cancer (CRC) cell lines displaying microsatellite instability (MSI) are resistant to 5-fluorouracil in vitro, which can be overcome by restoring DNA mismatch repair (MMR) competence. Furthermore, elevated levels of Bcl-2 protein confers cytotoxic drug resistance to tumour cell lines. We examined the expression of Bcl-2 and two MMR proteins (hMLH1 and hMSH2) in advanced CRC patients, to determine their mutual relationship, association to therapeutic response and impact on disease outcome. Tumour samples from 73 CRC patients who were treated in advanced stage with either irinotecan alone or in combination with 5-FU/leucovorin, were analysed for expression of Bcl-2, hMLH1 and hMSH2 using immunohistochemistry. Bcl-2 expression was closely correlated with hMLH1 and hMSH2 expression (negative-weak/moderate-strong) (p=0.01). Bcl-2/MMR expression was significantly (p=0.030 for whole series; p=0.018 for the 5-FU-treated cases) related to the response to treatment; tumours with low levels of both Bcl-2 and MMR responded better (n=18/31, 58%) than those with high Bcl-2 and MMR (n=3/16, 18%). Patients with high Bcl-2/MMR expression had a significantly longer DFS (47 vs. 11 months, n=26) than those with low Bcl-2/MMR index (p=0.005). Bcl-2/MMR index was not significantly related to disease-specific survival or survival with metastases. The present data suggest that MSI patients with low Bcl-2/MMR demonstrate a significantly shorter DFS, whereas patients with high expression of the two markers obtain the greatest benefit from 5-FU-based chemotherapy.

Related Articles

Journal Cover

November 2008
Volume 20 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bendardaf R, Lamlum H, Ristamäki R, Syrjänen K and Pyrhönen S: Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer. Oncol Rep 20: 999-1004, 2008.
APA
Bendardaf, R., Lamlum, H., Ristamäki, R., Syrjänen, K., & Pyrhönen, S. (2008). Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer. Oncology Reports, 20, 999-1004. https://doi.org/10.3892/or_00000101
MLA
Bendardaf, R., Lamlum, H., Ristamäki, R., Syrjänen, K., Pyrhönen, S."Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer". Oncology Reports 20.5 (2008): 999-1004.
Chicago
Bendardaf, R., Lamlum, H., Ristamäki, R., Syrjänen, K., Pyrhönen, S."Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer". Oncology Reports 20, no. 5 (2008): 999-1004. https://doi.org/10.3892/or_00000101